Table 3. Survival of 5-FU refractory pts treated with either O or I in clinical trials.

	Overall survival
	6-month (%)		12-month (%)		Median (months)
Study	I	O	I	O	I	O	P-value
Second-line
(Fuchs et al, 2003)	70	—	41	—	9.9	—
(Maughan, 2005)	80	83	57	60	14.8	15.2	NS
(Haller et al, 2004)	73	82 (I+O)	48	57 (I+O)	11.1	13.4 (I+O)	0.0072
Third-line
(Rowland et al, 2005)	71	75	35	39	8.7	10	NS

I, irinotecan; NS: nonsignificant; O, oxaliplatin.